Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;76(11):1635-1644.
doi: 10.1002/art.42939. Epub 2024 Aug 26.

Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index

Laura Ross  1 , Dylan Hansen  2 , Susanna Proudman  3 , Dinesh Khanna  4 , Ariane L Herrick  5 , Wendy Stevens  2 , Murray Baron  6 , Mandana Nikpour  7 ; Australian Scleroderma Interest Group (ASIG), Canadian Scleroderma Research Group (CSRG), the Scleroderma Clinical Trials Consortium Activity Index Working Group
Collaborators, Affiliations

Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index

Laura Ross et al. Arthritis Rheumatol. 2024 Nov.

Abstract

Objective: Accurate measurement of disease activity in systemic sclerosis (SSc) remains a significant clinical challenge. The Scleroderma Clinical Trials Consortium (SCTC) convened an Activity Index (AI) Working Group (WG) to develop a novel measure of disease activity (SCTC-AI).

Methods: Using consensus methodology, we developed a conceptual definition of disease activity. Literature review and expert consensus generated provisional SCTC-AI items, which were reduced by Delphi survey. Provisional items were weighted against a combined endpoint of morbidity and mortality, using time-dependent Cox proportional hazards regression analysis of the Australian Scleroderma Cohort Study (ASCS) (n = 1,254). External validation of the SCTC-AI was performed using data collected from 1,103 Canadian Scleroderma Research Group Study participants.

Results: Disease activity in SSc was defined using consensus methodology as "aspects of disease that are reversible, or can be arrested, with time and, or effective therapy." One-hundred and forty-one provisional SCTC-AI items were generated and reduced using three rounds of Delphi survey and statistical reduction and weighting, against mortality and quality of life measures, yielding a final 24-item index with a maximum possible score of 140. Survival analysis in an external cohort showed a graded relationship between disease activity scores and survival (P < 0.01).

Conclusion: We present a novel instrument to quantify the burden of disease activity in SSc. We have employed a rigorous consensus-based process in combination with data-driven methods to develop an instrument that has face, content, and criterion validity. Further work is required to fully validate and confirm the construct and discriminative validity of the SCTC-AI.

PubMed Disclaimer

References

REFERENCES

    1. Cutolo M, Soldano S, Smith V. Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev Clin Immunol 2019;15(7):753−764.
    1. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient‐generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40(11):1984−1991.
    1. Clements P. Measuring disease activity and severity in scleroderma. Curr Opin Rheumatol 1995;7:517−521.
    1. Medsger TA Jr, Bombardieri S, Czirjak L, et al. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003;21(suppl 29):S42−S46.
    1. Ross L, Baron M, Nikpour M. The challenges and controversies of measuring disease activity in systemic sclerosis. J Scleroderma Relat Disord 2018;3(2):115−121.

Publication types

LinkOut - more resources